DanCann Pharma was founded in 2018 and is a Danish pharmaceutical company. DanCann Pharma focuses on discovering, developing, manufacturing, and commercializing cannabinoid therapeutics in a broad range of disease areas. The company makes prescription (Rx-pharmaceuticals) and over-the-counter (OTC) pharmaceuticals mainly focused on pain patients with alternative needs and management to handle their illness, covered by the Danish Pilot Programme for medical cannabis.

Quotes for DanCann Pharma A/S

Right Now

+/-
0.002
%
7,69%
Latest
0.028
High
0.0294
Low
0.026
Volume
1 319 461
Turnover (DKK)
35 796
Market Value (MDKK)
4,0
Time (Latest trade)

Board

CEO

  • Jeppe Krog Rasmussen

Chairperson of the Board

  • Carsten Trads

Board

  • Jeppe Krog Rasmussen
  • Alexander Schoeneck
  • Christian Carlsen
  • Tue Østergaard

Largest Owners

Name Capital % Votes % Date
Nordic Growth Opportunities 2 41,30 41,30 2024-01-10
Sellers of CannGros ApS 7,85 7,85 2021-10-05
Alexander Schoeneck 6,21 6,21 2022-06-30
Futur Pension 5,56 5,56 2021-09-30
Jeppe Krog Rasmussen 4,18 4,18 2023-11-30
Morten Martinsen 1,41 1,41 2021-12-30
Hansen & Nytoft Invest Aps 1,34 1,34 2021-08-19
Tue Østergaard 1,28 1,28 2022-12-31
Vavi Invest Aps 0,88 0,88 2021-08-19
Carsten Trads 0,63 0,63 2022-12-31
Holdings by Modular Finance AB. Compiled and processed data from various sources, including VP Securities, Morningstar and The Danish Financial Supervisory Authority (Finanstilsynet)

Insider trading

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2024-04-17 Delårsrapport Q3 2024

  • 2024-05-30 Årsstämma 2023

  • 2024-05-31 Delårsrapport 2024-Q1

  • 2024-08-30 Delårsrapport 2024-Q2